DeepMatter (DMTR) announced on Monday a collaboration with pharmaceutical giant AstraZeneca (AZN) to use DeepMatter’s DigitalGlassware™ platform.
The collaboration hopes to improve the productivity of synthesising single compounds and compound libraries based on unique, structured data harvested from DeepMatter’s platform.
The DigitalGlassware™ platform allows chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud.
Mark Warne, CEO of DeepMatter, said: "We've been impressed with the automated chemistry platforms developed at AstraZeneca sites for autonomous delivery of new lead series.”
He added: “We see an opportunity to draw together knowledge from the DigitalGlassware™ platform to enable machine learning and AI technologies to increase the certainty of producing a high quality and choice of candidate drug molecules.”
"We look forward to progressing this exciting collaboration over the coming months as we continue to maximise the potential of the DigitalGlassware™ platform."
Shares in DeepMatter were trading 46.34% higher at 3p on Monday
Michael Kossenjans, Associate Director, Discovery Sciences, R&D, AstraZeneca, said: "Our goal is to transform drug design using innovative digital technologies in combination with automation and AI.”
“To get potential new medicines to patients faster, we need to reduce the cycle time for lead identification and optimisation and look forward to working with DeepMatter to assess the potential of DigitalGlassware™ to help with this."
DigitalGlassware™ was launched a year ago with seven unnamed partners who DeepMatter said were multinational life science companies, research institutions and leading academic institutions.
Follow News & Updates from DeepMatter here: